Following Successful Deployment, Airports in Belgium Place Follow-On Order for Implant Sciences' QS-B220s
13 additional units sold as Implant Sciences sees residual ECAC demand
WILMINGTON, Mass., Oct. 21, 2015 /PRNewswire/ -- Implant Sciences Corporation (OTCQB: IMSC), a leading manufacturer of explosives trace detection (ETD) and drugs trace detection solutions for homeland security applications, today announced that it has received a follow-on order for 13 additional QS-B220 Desktop Explosives Trace Detectors, which will be deployed at airports in Belgium.
Under new regulations adopted in Europe, implementation of ETD screening at EU airports with over 500,000 annual passengers was mandated to be in place by September 1, 2015. As part of this initial mandated deployment, airports in Belgium initially had purchased and successfully deployed 33 of Implant Sciences' QS-B220s for passenger checkpoint screening.
"Although the date for mandatory implementation of ETD systems in larger European airports has passed, we are continuing to see demand for our QS-B220 in this vertical and region," stated Dr. Darryl Jones, Implant Sciences' Executive Vice President. "We do not view the impact of the EU regulations as driving a single purchasing period from EU airports. Rather, as evidenced by this follow-on order in Belgium, we expect to continue to see demand for our units from these airports and from regional airports in Europe, where mandatory ETD screening regulations will take effect in March 2017."
"As we continue to provide security solutions to these high-profile customers, not only do we see the initial positive impact to our revenue, but our long-term pipeline also increases significantly," added Dr. Bill McGann, CEO of Implant Sciences. "We are pleased that customers, like the airports in Belgium, have chosen Implant Sciences for their initial ETD deployment, and the follow-on orders are evidence of their trust in our systems and value proposition as they continue to expand their use of ETD."
About the QS-B220 Desktop Explosives Trace Detector
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.
About Implant Sciences
Implant Sciences is a leader in developing and manufacturing advanced detection capabilities to counter and eliminate the ever-evolving threats from explosives and drugs. The Company's team of dedicated trace detection experts has developed proprietary technologies used in its commercial products, thousands of which have been sold across more than 70 countries worldwide. The Company's ETDs have received approvals and certifications from several international regulatory agencies including the TSA in the U.S., ECAC in Europe, CAAC and the Ministry of Public Safety in China, Russia FSB, STAC in France, and the German Ministry of the Interior. It has also received the 2015 GSN Airport/Seaport/Border Security Award for "Best Security Checkpoint". All Implant Sciences products are recognized as Qualified Anti-Terrorism Technologies by the Department of Homeland Security. For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.
Cautionary Note Regarding Forward-Looking Statements
This press release and any statements of employees, representatives and partners of Implant Sciences Corporation (the "Company") related thereto contain or may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. Such statements are based on management's current expectations and are subject to significant risks and uncertainties (many of which are beyond the Company's control) that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that there is no guaranty that the Transportation Security Administration (TSA) or any other U.S. or foreign government and law enforcement agencies or commercial consumers will purchase any of our explosives detection products or that any new products we may develop will be accepted by the TSA or by such other governments, agencies or consumers; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change, and our ability to generate revenue and profit will depend on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. In light of these risks and uncertainties, readers are cautioned that actual results may differ significantly from those described or anticipated in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.
Contact:
Implant Sciences Corporation
Company Contact:
Robert Liscouski
978-752-1700 x 116
SOURCE Implant Sciences Corporation
Share this article